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Background: The use of imaging to implement on-treatment adaptation of radiotherapy is a promising paradigm
but current data on imaging changes during radiotherapy is limited. This is a hypothesis-generating pilot study to
examine the changes on multi-modality anatomic and functional imaging during (chemo)radiotherapy treatment
for head and neck squamous cell carcinoma (HNSCC).
Methods: Eight patients with locally advanced HNSCC underwent imaging including computed tomography (CT),
Fluorine-18 fluorodeoxyglucose (FDG) positron emission tomography (PET)-CT and magnetic resonance imaging
(MRI) (including diffusion weighted (DW) and dynamic contrast enhanced (DCE)) at baseline and during (chemo)
radiotherapy treatment (after fractions 11 and 21). Regions of interest (ROI) were drawn around the primary tumour
at baseline and during treatment. Imaging parameters included gross tumour volume (GTV) assessment, SUVmax,
mean ADC value and DCE-MRI parameters including Plasma Flow (PF). On treatment changes and correlations
between these parameters were analysed using a Wilcoxon rank sum test and Pearson’s linear correlation coefficient
respectively. A p-value <0.05 was considered statistically significant.
Results: Statistically significant reductions in GTV-CT, GTV-MRI and GTV-DW were observed between all imaging
timepoints during radiotherapy. Changes in GTV-PET during radiotherapy were heterogeneous and non-significant.
Significant changes in SUVmax, mean ADC value, Plasma Flow and Plasma Volume were observed between the
baseline and the fraction 11 timepoint, whilst only changes in SUVmax between baseline and the fraction 21 timepoint
were statistically significant. Significant correlations were observed between multiple imaging parameters, both
anatomical and functional; 20 correlations between baseline to the fraction 11 timepoint; 12 correlations between
baseline and the fraction 21 timepoints; and 4 correlations between the fraction 11 and fraction 21 timepoints.
Conclusions: Multi-modality imaging during radiotherapy treatment demonstrates early changes (by fraction 11) in
both anatomic and functional imaging parameters. All functional imaging modalities are potentially complementary
and should be considered in combination to provide multi-parametric tumour assessment, to guide potential
treatment adaptation strategies.
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The use of radiotherapy ± chemotherapy is now estab-
lished as a standard of care in the management of locally
advanced head and neck squamous cell carcinoma
(HNSCC), both for unresectable disease [1] and organ
preservation [2]. Intensity modulated radiotherapy
(IMRT) has been widely adopted for the treatment of
HNSCC [3]. IMRT along with image guided radiotherapy
(IGRT) can provide a highly conformal dose distribution
with steep dose gradients, sparing critical adjacent organs
at risk.
Despite the increasing complexity and high degree of
conformality of modern radiotherapy techniques, radi-
ation therapy is routinely planned on a pre-treatment
‘planning’ computed tomography (CT) scan acquired at
a single timepoint. A further concept is that of adaptive
radiotherapy, which takes into account patient and/or
tumour changes which occur during treatment [4].
Treatment modifications are commonly only made in
the event of on-treatment problems such as significant
weight loss or mask fitting problems. However, it is
recognized that tumours respond variably during a
course of fractionated radiotherapy [5]. An assessment
of this response to treatment may allow a timely
individualization of treatment. For example, if on-
treatment imaging was an accurate response prediction
tool, imaging changes could be used to guide dose escal-
ation in the event of an inadequate early response [6], or
a de-intensification of therapy in light of a favorable
early response in order to maximize therapeutic ratio.
Future clinical trials are likely to increasingly test adap-
tive approaches individualising therapy.
In order to develop adaptive radiotherapy strategies,
imaging biomarkers are needed to determine prognostic-
ally significant early tumour changes during treatment.
Computed tomography (CT) remains the mainstay of
radiotherapy planning, providing accurate geometrical
data along with electron density maps to allow dose cal-
culation. However, low soft tissue resolution and dental
artifacts hinder tumour delineation with CT, as shown
by wide inter-observer variability in contouring head
and neck tumours on planning CT scans [7]. Anatomic
magnetic resonance imaging (MRI) sequences provide
excellent soft tissue contrast, and can reduce inter-
observer variability in target contouring [8,9]. Functional
imaging may offer information on factors which influence
treatment outcomes, e.g. tumour cellularity, perfusion,hypoxia. Fluorine-18 fluorodeoxyglucose (FDG) positron
emission tomography (PET) is the most widely used func-
tional imaging modality in head and neck cancer and is
commonly combined with CT (PET-CT) providing add-
itional biological information about tumours complemen-
tary to anatomic imaging [9,10]. FDG is a widely used
radiolabelled glucose analogue taken up by metabolically
active cells. Functional MRI sequences also provide bio-
logical tumour information. Diffusion weighted MRI
(DW-MRI) relies upon the free and random diffusion of
water molecules with restricted diffusion occurring in
highly cellular areas of a tumour; the degree of diffusion
restriction is quantified by the apparent diffusion coeffi-
cient (ADC) value. Baseline DW-MRI has been shown to
predict local control of HNSCC [11]. Dynamic contrast
enhanced MRI (DCE-MRI) provides a signal which is re-
lated to the underlying perfusion and permeability of the
tumour microenvironment. DCE-MRI characteristics have
been found to be predictive of short term treatment re-
sponses [12,13]. Current available data regarding imaging
changes during radiotherapy are limited [14]. Important
questions arise with regard to i) which is the most
suitable imaging modality to assess early response
during treatment, and ii) what is the optimal timing
of on-treatment imaging assessments to guide adaptive
radiotherapy strategies.
In this hypothesis generating pilot study, we aim to
examine on-treatment changes occurring on CT, FDG
PET-CT and MRI including DW-MRI and DCE-MRI
sequences in the primary tumour which may potentially
guide selection of imaging modality and timing for
response assessment studies.
Methods
Inclusion criteria
Inclusion criteria for this prospective single centre pilot
study were as follows: age ≥18 years old, histologically
proven squamous cell carcinoma of the head and neck
region, WHO performance status 0-2, decision to
proceed with (chemo)radiotherapy with curative intent
following discussion in a multi-disciplinary meeting,
measurable primary cancer on routine pre-treatment im-
aging (CT and/or MRI), and provision of fully informed
consent. Patients were excluded from the study if there
was poorly controlled diabetes, contraindication to MRI
or an estimated glomerular filtration rate <30 ml/min/
1.73 m2. This study was approved by the Research
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Yorkshire and the Humber-Bradford, 11/YH/0212) and
Administration of Radioactive Substances Advisory
Committee (ARSAC).
Treatment
All patients underwent 70 Gy of radiotherapy delivered
in 35 once daily fractions delivered over a period of
7 weeks as per departmental protocol. Treatment was
delivered using a 5-7 field step-and-shoot IMRT tech-
nique. Standard concurrent chemotherapy was cisplatin
at a dose of 100 mg/m2 on days 1 and 29. Cetuximab
was delivered if cisplatin was contraindicated, at a dose
of 400 mg/m2 on day -7 and then weekly at a dose of
250 mg/m2 during radiotherapy.
Imaging schedule
The imaging schedule was performed as part of the clin-
ical study. Baseline imaging consisted of FDG PET-CT
and MRI scans. Repeat FDG PET-CT and MRI scans
during radiotherapy were performed +/- 3 days of deliv-
ering fractions 11 and 21, which were approximately 2
and 4 weeks from the commencement of radiotherapy,
respectively.
Image acquisition
FDG PET-CT
FDG PET-CT imaging was performed on a 64-section
GE Discovery 690 PET-CT system (GE Healthcare,
Amersham, UK). Baseline half-body PET acquisition
with a dedicated head and neck acquisition (3-4 bed po-
sitions, 2 minutes per bed position) from skull vertex to
carina was performed 60 minutes following a 400 MBq
injection of intravenous FDG. The CT component of the
head and neck acquisition was obtained after a 25 second
delay following a bolus of 100 mls of iodinated contrast
(Niopam 300, Bracco Ltd, High Wycombe, UK) injected
at 3 ml/s using the following settings; 120 kV, variable
mA (min 10, max 600, noise index 12.2), tube rotation
0.5 s per rotation, pitch 0.969 with a 2.5 mm section
reconstruction. The contrast-enhanced CT component
of the PET-CT scan, acquired with a 5-point thermo-
plastic radiotherapy immobilization mask fitted and
room laser alignment, was also used for radiotherapy
planning according to routine clinical protocols. The
remainder of the PET acquisition from symphysis menti
to upper thighs was acquired following this with a
delayed post-contrast CT component using similar
scan acquisition parameters and a contiguous 3.5 mm
reconstruction.
During radiotherapy, only a dedicated head and neck
PET acquisition was performed with an accompanying
contrast-enhanced CT component using the same PET
and CT imaging parameters detailed above.MRI
Images were acquired on a 1.5 T Siemens Magnetom
Avanto (Siemens Healthcare, Erlangen, Germany). The
following sequences were acquired in the standard
diagnostic position using a dedicated head/neck coil;
single shot EPI diffusion-weighted images (b = 0, 400
and 800 s/mm2, TR = 6200 ms, TE = 89 ms, 40 x 4 mm
thick slices with a 1 mm slice gap, acquired voxel
size = 1.2 x 1.2 x 4.0 mm voxel), 3D spoiled gradient
echo dynamic contrast enhanced scan (TR = 3.23 ms,
TE = 0.93 ms, flip angle =21°, 40 x 5 mm slices, 2.5 s
temporal resolution, 150 time points, acquired voxel
size = 2.4 x 1.8 x 7.1 mm), axial post-contrast T1-
weighted spin echo image (TR = 831 ms, TE = 8.6 ms,
105 x 2 mm thick contiguous slices, acquired voxel
size = 0.9 x 0.9 x 2.0 mm). The patient was repositioned
in the radiotherapy immobilization device and the axial
post-contrast T1-weighted image was repeated as well
as a fat saturated T2-weighted scan (TR = 4430 ms,
TE = 76 ms, voxel size = 0.8 x 0.7 x 3.0 mm). A contrast
agent (0.2 ml/kg Dotarem, Guerbet, France, 3 ml/sec)
was injected after approximately 10 measurements of the
3D spoiled gradient echo sequence.
Image analysis
In each imaging modality, assessment of the primary
tumour was carried out as detailed below by a single
experienced head and neck radiologist (MS 6 years of
experience).
FDG PET-CT
Image analysis was undertaken on a dedicated PET
workstation (Advantage Windows, version 4.5, GE
Healthcare, Amersham, UK). The maximum tumour
standardized uptake value (SUVmax) was derived by
drawing a region of interest (ROI) encompassing the pri-
mary tumour, which defined the gross tumour volume
(GTV) on PET. This was achieved by using an adaptive
thresholding technique, known as the Homburg algo-
rithm [15], calculated from the mean primary tumour
SUV (SUVmean) when applying a 70% of SUVmax isocon-
tour, the background tissue SUVmean and two scanner
specific coefficients (determined from phantom studies).
CT, MRI
Image analysis was undertaken using XD3 software
(Mirada Medical, Oxford, UK). GTV-CT was defined as
the volume of enhancing tumour, whilst the GTV-MRI
was defined as the area of high signal representing
tumour on the T2-weighted image using the T1-
weighted images for anatomic cross reference. DW-MRI
analysis was undertaken on a Leonardo workstation
(Siemens Healthcare, Erlangen, Germany). Analysis con-
sisted of visual contouring of the area of restricted
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using both the T1- and T2-weighted images for anatomic
cross reference, to calculate the GTV-DW. These con-
tours were applied to the accompanying apparent diffu-
sion coefficient (ADC) maps, calculated from the single
shot EPI sequence, and a mean ADC value was calculated
for each ROI.
DCE-MRI analysis was undertaken using validated in-
house software, PMI 0.4 [16]. An arterial input function
was measured by selecting the single brightest pixel in
the internal carotid artery on a map of the maximal
signal enhancement. A plasma flow map was calculated
by deconvolution and the entire primary tumour was
visually outlined on this map using the T1- and T2-
weighted images for anatomic cross reference. Tissue
concentration-time curves in the primary tumour were
fitted to a two compartment exchange model, producing
functional DCE-MRI parameters including Plasma
Flow (PF), Plasma Volume (PV), Interstitial Volume
(also known as Extravascular Extracellular Space, νe),
Permeability Surface Area Product (PS), Extraction
Fraction (EF) and Ktrans each of which reflect different
physiologic parameters within the tumour microenviron-
ment [17]. All concentrations were approximated by sub-
traction of the baseline signal.
Statistical analysis
Patient characteristics were recorded at baseline. Percent
change in multi-parametric measurements occurring
during treatment were analysed using a Wilcoxon rank
sum test using the Statistics Toolbox of Matlab R2013b
with the null hypothesis that the median percentage
change is zero. Correlations between parameters were
performed using Pearson’s linear correlation coefficient,
also in Matlab R2013b. A p-value of < 0.05 was consid-
ered statistically significant.
Results
Eight patients entered the study between November
2011 and June 2012. All completed treatment with a me-
dian follow up of 24 months (range 13-28). PatientTable 1 Patient demographics and tumor characteristics
Patient Primary tumor site T-stage N-stage Differen
1 Oropharynx, tonsil 2 2b Poorly
2 Supraglottis, Epiglottis 3 2b Well
3 Hypopharynx, pyriform fossa 3 0 Moderate
4 Oropharynx, base of tongue 4a 1 Poorly
5 Oropharynx, base of tongue 2 1 Poorly
6 Oropharynx, base of tongue 2 2b Moderate
7 Oropharynx, base of tongue 2 2b Poorly
8 Oropharynx, base of tongue 1 2b Poorlydemographics and tumour characteristics are shown in
Table 1. Seven patients were treated with concurrent cis-
platin; one patient (patient 4) received concurrent cetux-
imab due to deafness contra-indicating cisplatin. All
patients completed treatment with 70 Gy in 35 fractions
over 7 weeks of radiotherapy. On follow up, 7 of 8 pa-
tients are disease free. One patient (patient 7) relapsed
with brain metastases with loco-regional control.
All patients completed imaging with FDG PET-CT and
MRI at baseline and at the fraction 11 timepoint. One
patient (patient 1) did not undergo further imaging at
the fraction 21 timepoint due to treatment-related tox-
icity. One patient (patient 2) did not undergo MRI at the
fraction 21 timepoint due to an MRI scanner technical
error. Six patients completed all imaging as planned
within the study. Baseline FDG PET-CT was performed
a median of 19 days pre-treatment (range 13-24). Base-
line MRI was performed a median of 8 days (range 2-16)
pre-treatment. FDG PET-CT and MRI at the fraction 11
timepoint took place at a median of -0.5 days (range -1
to +3) and 0 days (range -1 to +2) from fraction 11
respectively. FDG PET-CT and MRI at the fraction 21
timepoint took place at a median of +1 (range -1 to +3)
and +2 days (range -2 to +4) from fraction 21 timepoint
respectively. Representative multi-modality images from
one patient (patient 7) are shown in Figure 1. During
analysis, the GTV was not identifiable on the CT for pa-
tient 1 due to dental amalgam. SUVmax measurement
was inaccurate due to high blood glucose on serial im-
aging for patient 1 (data not shown). All other images
acquired were suitable for interpretation.
The anatomic primary tumour volumes as contoured
on CT, MRI and DW-MRI (GTV-CT, GTV-MRI and
GTV-DW respectively) at serial timepoints, progres-
sively reduced to varying degrees during treatment for
all patients (Figure 2). Statistically significant percentage
reductions in multi-modality anatomic primary tumour
volumes (Wilcoxon Ranked Sum, p < 0.05, no correction
for repeated measures) were observed between all im-
aging timepoints (Figure 3, Table 2). GTV-PET showed a
decrease in 5 patients between baseline and the fractiontiation GTVMR (cm
3) Follow-up (months) Disease recurrence
3.0 28 No
14.7 27 No
ly 4.0 28 No
32.8 25 No
10.6 24 No
ly 6.4 20 No
16.7 13 Distant metastases
2.0 21 No
Figure 1 Multi-modality imaging changes during radiotherapy. A case of a patient with a poorly differentiated squamous cell carcinoma of
the base of tongue, T2N2bM0 treated with concurrent chemoradiotherapy to a dose of 70 Gy in 35 fractions over 7 weeks with concurrent
cisplatin 100 mg/m2 days 1 and day 29. Imaging was acquired at baseline, fraction 11 and fraction 21 timepoints. Representative axial images at
each timepoint are shown, illustrating CT, T2-weighted MRI, DW-MRI, DCE-MRI, and FDG PET-CT images. Colourwash panels show intensity of FDG
uptake and PF.
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between the fraction 11 and fraction 21 timepoints;
these percentage changes in metabolic tumour volume
did not reach statistical significance.
The multi-parametric functional measurements showed
varied changes at serial timepoints during radiotherapy
(Figure 2). SUVmax decreased from baseline to fraction 11
in all patients and fell further at the fraction 21 timepoint
in 6 of 7 patients; the percentage change between base-
line and the fraction 11 and fraction 21 timepoints was
statistically significant (p = 0.016). The mean ADC value
increased from baseline to the fraction 11 timepoint in
all patients and showed a further increase at the frac-
tion 21 timepoint in 4 of 6 patients; the percentage
change between baseline and the fraction 11 timepoint
was statistically significant (p = 0.008). Plasma Flow pro-
gressively increased in all patients at fraction 11 com-
pared with baseline; 5 of 6 patients showed a further
increase at the fraction 21 timepoint., However, only
percentage changes in Plasma Flow and Plasma Volume
between baseline and the fraction 11 timepoint reached
statistical significance (p = 0.0078, p = 0.0078), whilst
percentage changes in νe, EF, PS and K
trans duringradiotherapy did not reach statistical significance
(Figure 3, Table 2).
There were several parameters that showed a signifi-
cant correlation between the percentage change (Δ)
from baseline to the fraction 11 timepoint; a full listing
of parameter pairs with significant correlation is given in
Table 3. ΔGTV-CT was correlated with ΔGTV-MRI
and ΔGTV-MRI was correlated with ΔGTV-PET.
However, ΔGTV-CT was not correlated with ΔGTV-PET
and ΔGTV-DW was inconsistently correlated with only
ΔGTV-MRI between the baseline and fraction 11 time-
point and ΔGTV-CT between the fraction 11 and fraction
21 timepoints. There were also negative correlations be-
tween both ΔGTV-CT and ΔGTV-MRI with some of the
DCE parameters (ΔKtrans, ΔPS, ΔEF, Δνe) and a positive
correlation with ΔSUVmax. Strong positive correlations
were observed between some of the DCE parameters. For
instance ΔKtrans had a near perfect correlation with ΔPS.
Discussion
Adaptive radiotherapy planning for HNSCC is a very
attractive goal to allow the early individualization of
treatment. Modern imaging techniques now offer the
Figure 2 Absolute changes in anatomical and functional imaging parameters during radiotherapy. Plots of GTV-CT, GTV-MRI, GTV-DW,
GTV-PET, SUVmax, mean ADC value (ADC), Plasma Flow (PF), Plasma Volume (PV), Interstitial Volume (νe), Permeability Surface Area Product (PS),
Extraction Fraction (EF) and Ktrans at baseline (B), fraction 11 (#11) and fraction 21 (#21) timepoints. ✶= median data point at each imaging
timepoint. Coloured lines represent individual patients.
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alterations during treatment. These imaging modalities
are candidates to provide an early response assessment,
which may be used to individually tailor treatment strat-
egy. This adaption could potentially take the form of
intensification or de-intensification of treatment based
upon early response. On-treatment imaging could also
be used to guide dose delivery, for example being used
to plan a radiotherapy boost.
With regard to anatomic imaging modalities, mean
anatomic volumes were reduced by > 30% at fraction 11and > 50% by fraction 21. Cao et al. [18] in a study of 14
patients reported a 28% reduction in tumour volume
after two weeks of treatment in those with locally con-
trolled disease. Dirix et al. [19] in a study of 15 patients
with various head and neck cancers (including 6 oropha-
ryngeal cancers) found an approximate halving of
tumour size after 4 weeks of radiotherapy, as assessed by
CT and MRI. Geets et al. [20] studied 18 patients with
pharyngo-laryngeal cancers, finding significant reduc-
tions in tumour size on CT and MRI following 46 Gy
of treatment. These consistent findings of substantial
Figure 3 Percentage changes in anatomical and functional imaging parameters during radiotherapy. Plots of percentage change in
GTV-CT, GTV-MRI, GTV-DW, GTV-PET, SUVmax, mean ADC value (ADC), Plasma Flow (PF), Plasma Volume (PV), Interstitial Volume (νe), Permeability
Surface Area Product (PS), Extraction Fraction (EF) and Ktrans at baseline (B), fraction 11 (#11) and fraction 21 (#21) timepoints. ✶= median percentage
change at each imaging timepoint. Coloured lines represent individual patients.
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head and neck tumour sites emphasizes the opportunity
for treatment strategies based around early treatment
responses.
The implementation of functional imaging techniques
to assess tumour response during treatment remains un-
certain. GTV-PET showed an initial reduction at the
fraction 11 timepoint in 5 patients but then a paradox-
ical increase in the same number of patients at the frac-
tion 21 timepoint. This was related to confounding peri-
tumoural inflammation and reducing tumour to back-
ground ratio resulting in difficulties in applying auto-
mated segmentation algorithms to contour metabolic
tumour volumes, which has been described previously
[21]. Moule et al. [22,23] reported on the use of serial
FDG PET in a series of 12 patients; SUVmax values
were found to progressively reduce during treatment.Background SUVmax was not found to alter significantly
with radiation dose, but because tumour uptake
dropped, thresholding methods were found to be unreli-
able in segmenting tumour from background [22,23].
Therefore these observations regarding GTV-PET are
likely due to limitations of segmentation algorithms ra-
ther than reflecting the underlying biological processes.
As shown in Figures 2 and 3 and Table 2, SUVmax was
found to consistently fall with significant reductions in
SUVmax from baseline observed during treatment. These
findings are consistent with other studies investigating
on-treatment FDG PET imaging [20,22-24]. Hentschel
et al. [24] have reported the largest series of 37 patients
who underwent serial FDG PET imaging at baseline and
at end of 1st or 2nd week (after 10 Gy or 20 Gy), 3rd or
4th week, and 5th or 6th week of radiotherapy. A >50%
reduction in SUVmax on FDG PET acquired after 10 Gy
Table 2 Median [range] and p-value of percentage change in parameters between imaging timepoints
(Baseline, Fraction 11 and Fraction 21)
Parameter Baseline to Fraction 11 Baseline to Fraction 21 Fraction 11 to Fraction 21
GTV-CT −24 [−78,−6] −53 [−82,−27] −23 [−53,−13]
(cm3) p = 0.016 p = 0.016 p = 0.016
GTV-MR −31 [−88,−3] −70 [−92,−61] −58 [−81,−32]
(cm3) p = 0.008 p = 0.031 p = 0.031
GTV-DW −53 [−77,−19] −79 [−93,−63] −62 [−73,−36]
(cm3) p = 0.008 p = 0.031 p = 0.031
GTV-PET −20 [−49,105] −16 [−69,374] 18 [−64,132]
(cm3) p = 0.375 p = 0.297 p = 0.578
SUVmax −26 [−84,−18] −60 [−78,−33] −19 [−47,36]
p = 0.016 p = 0.016 p = 0.219
Mean ADC value 37 [6,64] 48 [−1,105] 16 [−37,41]
(x10−3mm2s−1) p = 0.008 p = 0.063 p = 0.563
Plasma Flow (ml/min/100 ml) 35 [15,205] 62 [35,77] 7 [4,54]
p = 0.008 p = 0.063 p = 0.063
Plasma Volume 36 [18,155] 31 [−32,45] −2 [−53,8]
(ml/100 ml) p = 0.008 p = 0.313 p = 0.625
Interstitial Volume 11 [−47,165] 99 [−6,213] 37 [18,129]
(ml/100 ml) p = 0.461 p = 0.125 p = 0.063
Permeability Surface Area Product (ml/min/100 ml) 12 [−33,240] 290 [1,481] 75 [21,360]
p = 0.313 p = 0.063 p = 0.063
Extraction Fraction (%) −21 [−62,150] 118 [−32,286] 55 [12,290]
p = 0.641 p = 0.313 p = 0.063
Ktrans (min−1) 16 [−28,222] 15 [−100,422] 41 [−100,307]
p = 0.148 p = 0.461 p = 0.742
Statistically significant results indicated in bold type.
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disease free and overall survival. By contrast with our re-
sults with FDG PET at fraction 21, the authors commen-
ted that it was commonly not possible to determine
SUVmax following 30-40 Gy of treatment due to therapy-
associated peri-tumoural inflammation.
Significant changes in mean ADC value were observed
during treatment (Figure 2, Figure 3 and Table 2). The
observed increase in ADC during treatment reflects re-
duced tumor cellularity and hence a likely response to
treatment. These findings are consistent with 3 prior
studies examining DW-MRI as a predictive imaging mo-
dality during chemoradiotherapy [19,25,26]. In the study
of 30 patients by Vandecaveye et al. [25], the change in
ADC value was predictive of 2 year loco-regional
control. Similarly, Kim et al. [26] of 40 patients, reported
an increase in ADC values measured on imaging one
week into a course of chemoradiotherapy to predict a
complete treatment response. Dirix et al. [19] previously
showed that tumour volume contoured on diffusionimaging reduced in volume during treatment; in
addition, and as we have found, tumour volume on dif-
fusion imaging appeared smaller than on anatomic MRI
throughout the study.
Only very limited data is available on DCE-MRI
changes during radiotherapy in the literature. In our co-
hort of 8 patients, significant alterations in Plasma Flow
and Plasma Volume were observed during treatment
(Figure 2, Figure 3 and Table 2). Cao et al. [18] similarly
observed an increase in Plasma Flow after 2 weeks of
radiotherapy. Plasma Flow is regarded as a key param-
eter in the context of radiotherapy and has been shown
to have a negative correlation with the degree of tumour
hypoxia [27]. Therefore the observed increases in plasma
flow during treatment may correlate with improved per-
fusion, reduced hypoxia and consequentially reduced
radioresistance. By contrast, patterns of alterations in
the commonly reported functional parameter Ktrans were
inconsistent. Dirix et al. [19] examined the use of DCE-
MRI during treatment and did not find useful information
Table 3 Statistically significant (p < 0.05) correlations
between percentage changes (Δ) in pairs of measured
volumes (GTV-CT, GTV-MR, GTV-DW, GTV-PET) and
functional parameters (SUVmax, mean ADC value (ADC),
Plasma Flow (PF), Plasma Volume (PV), Interstitial
Volume (νe), Permeability Surface Area Product (PS),
Extraction Fraction (EF) and Ktrans)
Time interval Parameter 1 Parameter 2 Correlation
coefficient
p-value
Baseline to
Fraction 11
ΔGTV-CT ΔGTV-MR 0.820 0.0239
ΔGTV-CT Δνe −0.923 0.0030
ΔGTV-CT ΔPS −0.874 0.0101
ΔGTV-CT ΔEF −0.885 0.0081
ΔGTV-CT ΔKtrans −0.872 0.0105
ΔGTV-CT ΔSUVmax 0.910 0.0044
ΔGTV-MR ΔGTV-DW 0.785 0.0210
ΔGTV-MR Δνe −0.817 0.0134
ΔGTV-MR ΔPS −0.973 0.0001
ΔGTV-MR ΔEF −0.887 0.0033
ΔGTV-MR Δ Ktrans −0.974 0.0000
ΔGTV-DW ΔPS −0.753 0.0311
ΔGTV-DW Δ Ktrans −0.754 0.0306
ΔPF ΔPV 0.969 0.0001
Δνe ΔPS 0.914 0.0015
Δνe ΔEF 0.983 0.0000
Δνe Δ K
trans 0.909 0.0018
ΔPS ΔEF 0.960 0.0002
ΔPS Δ Ktrans 1.000 0.0000
ΔEF Δ Ktrans 0.955 0.0002
Baseline to
Fraction 21
ΔGTV-CT ΔGTV-DW 0.851 0.0316
ΔGTV-CT ΔPF 0.926 0.0237
ΔGTV-MR ΔADC 0.887 0.0185
ΔGTV-MR ΔPS −0.954 0.0118
ΔGTV-MR ΔEF −0.962 0.0088
ΔGTV-MR Δ Ktrans −0.964 0.0019
ΔADC Δ Ktrans −0.847 0.0334
ΔPF Δνe −0.936 0.0191
ΔPF ΔSUVmax 0.934 0.0203
ΔPS ΔEF 0.981 0.0032
ΔPS Δ Ktrans 1.000 0.0000
ΔEF Δ Ktrans 0.981 0.0030
Fraction 11 to
Fraction 21
ΔGTV-DW ΔPF 0.899 0.0381
ΔPS ΔEF 0.972 0.0057
ΔPS Δ Ktrans 1.000 0.0000
ΔEF Δ Ktrans 0.967 0.0073
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Ktrans and PS found in this study are indicative of high
plasma flow compared to PS. This suggests that the uptake
of contrast is limited by the permeability of the vessels
rather than in-flow.
One key question to guide future studies is which im-
aging modality or combination of techniques should be
used to provide early response prediction. Multiple cor-
relations were observed between both anatomic and
functional imaging parameters (Table 3) but it remains
unclear as to which combination is optimal. Some im-
aging techniques are not widely available and are more
difficult to implement into routine clinical practice. A
limited number of studies to date have examined the
value of on-treatment imaging as an early predictor of
outcome. Changes on early on-treatment imaging with
FDG PET [24] and FLT PET [28] have been shown to
correlate with disease outcomes. The data presented
here confirms that marked changes occur early during
treatment in both anatomic and functional imaging. In
terms of percentage changes compared with baseline, no
single imaging modality appears superior. Our data is
limited by its small sample size and loco-regional disease
control within the treatment field in all patients, both of
which preclude any useful correlation with outcome.
However, from these data, anatomic imaging with CT or
MRI, or functional data derived from FDG PET, DW- or
DCE-MRI are all candidate imaging modalities to inves-
tigate early response predictors. Decisions on which
imaging parameters are most likely to be clinically valu-
able will depend to a certain extent upon the availability
and logistics of imaging. The advent of combined PET/
MR scanners may be valuable in advancing these multi-
modality imaging approaches, allowing acquisition of
multiple modalities at one scan session.
Adoption of an adaptive treatment strategy requires
the availability of prognostic information as early as pos-
sible during treatment. Image acquisition after fraction
11 and fraction 21 of radiotherapy was aimed at identifi-
cation of a potential imaging timepoint upon which fur-
ther exploratory studies looking at prognostic value of
imaging biomarkers be based upon. Marked changes
occur early during treatment in both anatomic and func-
tional imaging readouts, although the magnitude of
change between fraction 11 and 21 timepoints was gen-
erally less than that seen at fraction 11 compared with
baseline. An earlier timepoint during treatment provides
more opportunity to allow treatment adaption. There-
fore, these results suggest that imaging after around
two weeks of treatment is the most suitable time-
point to investigate in future studies examining treatment
adaptation.
There are several limitations to this study. Patient
numbers are small, and in particular two patients did
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timepoint. This will have restricted the ability of the data
to demonstrate significant associations in imaging changes
from baseline and fraction 11 to fraction 21. A further
possible limitation of this analysis is the method by which
ROIs were constructed on functional imaging modalities.
Limitations in FDG PET based tumour contouring during
treatment are detailed above and the optimal method of
segmenting PET imaging to define the tumour edge
remains uncertain and controversial [29]. ROIs for DW-
MRI and DCE-MRI were created with visual cross-
reference to T1- and T2- weighted imaging but geometric
distortions are known to preclude the current use of DW-
MRI for tumour delineation for radiotherapy planning
[30]. An alternative method using spatial co-registration of
imaging modalities may have enabled more accurate con-
struction and reproducible regions of interest. However,
even with this methodology, there are potential errors in
co-registration and uncertainties in which imaging modal-
ity most accurately reflects tumour volumes [31,32]. We
adopted a pragmatic approach that would be readily ap-
plicable to clinical practice, although ongoing work is
examining the spatial correlation of on-treatment multi-
modality imaging changes.
Conclusion
In summary, significant alterations with anatomic and
functional imaging of the primary tumour were observed
early (by fraction 11) in treatment. Significant but vari-
able correlations between different imaging modalities
existed. Each of these imaging modalities, either alone or
in combination, remains a candidate to provide an early
biomarker of outcome. The study confirms the potential
of multi-parametric tumour assessment during radio-
therapy to guide treatment adaptation strategies. Future
studies will need to correlate each modality alone or
in combination with outcome, to determine their rela-
tive value as imaging biomarkers to guide treatment
individualization and adaption.
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